The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

Inclusion Criteria:

• Patients with Generalized Social Anxiety Disorder as the primary diagnosis.
• If female, must commit to consistent and correct use of an acceptable method of birth control.

Exclusion Criteria:

• Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening.
• Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder.
• Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal.
• Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months.
• Patients with an unstable medical disorder.
• Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study.
• Patients who are taking other psychoactive medications.

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.